How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

12,211 results for

General Medical Books

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. Lonoctocog alfa (haemophilia A) - Benefit assessment according to §35a Social Code Book V

Lonoctocog alfa (haemophilia A) - Benefit assessment according to §35a Social Code Book V 1 Translation of addendum A16-66 Elotuzumab (multiples Myelom) – Addendum zum Auftrag A16-32 (Version 1.0; Status: 9 November 2016). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 9 November 2016 1.0 Commission: A16-66 Version: Status: IQWiG Reports – Commission (...) Gemeinsamer Bundesausschuss (Federal Joint Committee) IQWiG Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (Institute for Quality and Efficiency in Health Care) ISS International Staging System MID minimally important difference MMRM mixed-effects model repeated measures PFS progression-free survival SAE serious adverse event SD standard deviation SGB Sozialgesetzbuch (Social Code Book) Addendum A16-66 Version 1.0 Elotuzumab – Addendum to Commission A16-32 9 November 2016 Institute

2017 Institute for Quality and Efficiency in Healthcare (IQWiG)

162. Idelalisib (chronic lymphocytic leukaemia) - Benefit assessment according to §35a Social Code Book V

Idelalisib (chronic lymphocytic leukaemia) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Idelalisib (chronische lymphatische Leukämie) – Nutzenbewertung gemäß § 35a SGB V (Version 1.1; Status: 5 January 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports (...) – Commission No. A16-64 Idelalisib (chronic lymphocytic leukaemia) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A16-64 Version 1.1 Idelalisib (chronic lymphocytic leukaemia) 5 January 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Idelalisib (chronic lymphocytic leukaemia) – Benefit assessment according to §35a Social Code Book V Commissioning agency

2017 Institute for Quality and Efficiency in Healthcare (IQWiG)

163. Lenvatinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V

und Wirtschaftlichkeit im Gesundheitswesen (Institute for Quality and Efficiency in Health Care) MSKCC Memorial Sloan Kettering Cancer Center PFS progression-free survival PT Preferred Term RCT randomized controlled trial SAE serious adverse event SGB Sozialgesetzbuch (Social Code Book) SMQ Standardized Medical Dictionary for Regulatory Activities Query SOC System Organ Class SPC Summary of Product Characteristics VEGF vascular endothelial growth factor Extract of dossier assessment A16-63 Version (...) the last dose of the study medication. Table 12 shows the risk of bias at study level. Table 12: Risk of bias at study level – RCT, direct comparison: lenvatinib + everolimus vs. everolimus Study Adequate random sequence generation Allocation concealment Blinding Reporting independent of the results No additional aspects Risk of bias at study level Patient Treating staff Study 205 Yes Yes No No Yes Yes Low RCT: randomized controlled trial; vs.: versus The risk of bias at study level for study 205

2017 Institute for Quality and Efficiency in Healthcare (IQWiG)

164. Trifluridine/tipiracil (colorectal cancer) - Benefit assessment according to §35a Social Code Book V

and scientific advice: ? Henning Schulze-Bergkamen, Clinic of Internal Medicine II, Marien-Hospital gGmbH, Wesel, Germany IQWiG thanks the medical and scientific advisor for his contribution to the dossier assessment. However, the advisor was not involved in the actual preparation of the dossier assessment. The responsibility for the contents of the dossier assessment lies solely with IQWiG. IQWiG employees involved in the dossier assessment 2 : ? Stefan Kobza ? Christiane Balg ? Charlotte Guddat ? Michaela (...) Trifluridine/tipiracil (colorectal cancer) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Trifluridin/Tipiracil (Kolorektalkarzinom) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 11 November 2016). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports

2017 Institute for Quality and Efficiency in Healthcare (IQWiG)

165. Saxagliptin/metformin - Benefit assessment according to §35a Social Code Book V

Saxagliptin/metformin - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Saxagliptin/Metformin (Diabetes mellitus Typ 2) – Nutzenbewertung gemäß § 35a SGB V (Ablauf Befristung) (Version 1.0; Status: 29 September 2016). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports (...) – Commission No. A16-43 Saxagliptin/metformin (type 2 diabetes mellitus) – Benefit assessment according to §35a Social Code Book V 1 (expiry of the decision) Extract of dossier assessment A16-43 Version 1.0 Saxagliptin/metformin (type 2 diabetes mellitus) 29 September 2016 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Saxagliptin/metformin (type 2 diabetes mellitus) – Benefit assessment according

2017 Institute for Quality and Efficiency in Healthcare (IQWiG)

166. Baricitinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V

Baricitinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.8 of the dossier assessment Baricitinib (Rheumatoide Arthritis) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 29 June 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A17-14 (...) Baricitinib (rheumatoid arthritis) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A17-14 Version 1.0 Baricitinib (rheumatoid arthritis) 29 June 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Baricitinib (rheumatoid arthritis) – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission awarded

2017 Institute for Quality and Efficiency in Healthcare (IQWiG)

167. Tenofovir alafenamide (chronic hepatitis B) ? Benefit assessment according to §35a Social Code Book V

Wirtschaftlichkeit im Gesundheitswesen (Institute for Quality and Efficiency in Health Care) IU international unit MedDRA Medical Dictionary for Regulatory Activities PT Preferred Term RCT randomized controlled trial SAE serious adverse event SGB Sozialgesetzbuch (Social Code Book) SMQ Standardized MedDRA Query SOC System Organ Class TAF tenofovir alafenamide TDF tenofovir disoproxil (fumarate) Extract of dossier assessment A17-13 Version 1.0 Tenofovir alafenamide (chronic hepatitis B) 29 June 2017 Institute (...) Tenofovir alafenamide (chronic hepatitis B) ? Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.7 of the dossier assessment Tenofoviralafenamid (chronische Hepatitis B) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 29 June 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports

2017 Institute for Quality and Efficiency in Healthcare (IQWiG)

168. Axitinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)

Axitinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision) Extract 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Axitinib (Nierenzellkarzinom) – Nutzenbewertung gemäß § 35a SGB V (Ablauf Befristung) (Version 1.0; Status: 29 June 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG (...) Reports – Commission No. A17-12 Axitinib (renal cell carcinoma) – Benefit assessment according to §35a Social Code Book V 1 (expiry of the decision) Extract of dossier assessment A17-12 Version 1.0 Axitinib (renal cell carcinoma) 29 June 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Axitinib (renal cell carcinoma) – Benefit assessment according to §35a Social Code Book V Commissioning

2017 Institute for Quality and Efficiency in Healthcare (IQWiG)

169. Dolutegravir (HIV infection) - Benefit assessment according to §35a Social Code Book V

Dolutegravir (HIV infection) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Dolutegravir (HIV-Infektion) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 28 June 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A17-11 Dolutegravir (HIV (...) infection) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A17-11 Version 1.0 Dolutegravir (HIV infection) 28 June 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Dolutegravir (HIV infection) – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission awarded on: 17 March 2017 Internal Commission

2017 Institute for Quality and Efficiency in Healthcare (IQWiG)

170. Pembrolizumab (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V

). The patients were treated until disease progression, unacceptable side effects, or study discontinuation due to decision by the physician or the patient. Treatment was generally restricted by the maximum number of allowed cycles. Following discontinuation of the study Extract of dossier assessment A17-06 Version 1.0 Pembrolizumab (non-small cell lung cancer) 10 May 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - 3 - medication (e.g. due to disease progression), the patients in both (...) Pembrolizumab (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Pembrolizumab (nicht kleinzelliges Lungenkarzinom) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 10 May 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports

2017 Institute for Quality and Efficiency in Healthcare (IQWiG)

171. Trametinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (Institute for Quality and Efficiency in Health Care) KRAS Kirsten rat sarcoma viral oncogene homologue MEK mitogen-activated extracellular signal-regulated kinase NGM Network Genomic Medicine NSCLC non-small cell lung cancer ORR objective response rate PFS progression-free survival RCT randomized controlled trial SGB Sozialgesetzbuch (Social Code Book) SPC Summary of Product Characteristics UICC Union for International Cancer Control (...) therapy from several options, the respective choice of the company is printed in bold. b: It is assumed for the present therapeutic indication that the NSCLC patients have stage IIIB to IV disease (staging according to IASLC, UICC), without a medical indication for curative resection, radiotherapy or radiochemotherapy. c: This applies especially to patients for whom nivolumab or cytotoxic chemotherapy is not an option due to their reduced general condition – in particular, these can be patients

2017 Institute for Quality and Efficiency in Healthcare (IQWiG)

172. Dabrafenib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (Institute for Quality and Efficiency in Health Care) KRAS Kirsten rat sarcoma viral oncogene homologue MEK mitogen-activated extracellular signal-regulated kinase NGM Network Genomic Medicine NSCLC non-small cell lung cancer ORR objective response rate PFS progression-free survival RCT randomized controlled trial SGB Sozialgesetzbuch (Social Code Book) SPC Summary of Product Characteristics UICC Union for International Cancer Control (...) Dabrafenib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Dabrafenib (nicht kleinzelliges Lungenkarzinom) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 28 July 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission

2017 Institute for Quality and Efficiency in Healthcare (IQWiG)

173. Nivolumab (squamous cell carcinoma of the head and neck) - Benefit assessment according to §35a Social Code Book V

Nivolumab (squamous cell carcinoma of the head and neck) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Nivolumab (Plattenepithelkarzinom des Kopf-Hals- Bereichs) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 30 August 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally (...) binding. IQWiG Reports – Commission No. A17-24 Nivolumab (squamous cell carcinoma of the head and neck) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A17-24 Version 1.0 Nivolumab (squamous cell carcinoma of the head and neck) 30 August 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Nivolumab (squamous cell carcinoma of the head and neck) – Benefit

2017 Institute for Quality and Efficiency in Healthcare (IQWiG)

174. Osimertinib (NSCLC) - Benefit assessment according to §35a Social Code Book V

Osimertinib (NSCLC) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Osimertinib (nicht kleinzelliges Lungenkarzinom) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 28 July 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A17-20 (...) Osimertinib (non-small cell lung cancer) – Benefit assessment according to §35a Social Code Book V 1 (expiry of the limitation period) Extract of dossier assessment A17-20 Version 1.0 Osimertinib (non-small cell lung cancer) 28 July 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - 1 - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Osimertinib (non-small cell lung cancer) – Benefit assessment according to §35a Social Code Book V Commissioning

2017 Institute for Quality and Efficiency in Healthcare (IQWiG)

175. Alectinib (NSCLC) - Benefit assessment according to §35a Social Code Book V

Alectinib (NSCLC) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Alectinib (nicht kleinzelliges Lungenkarzinom) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 28 July 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A17-19 Alectinib (...) (non-small cell lung cancer) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A17-19 Version 1.0 Alectinib (non-small cell lung cancer) 28 July 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Alectinib (non-small cell lung cancer) – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission

2017 Institute for Quality and Efficiency in Healthcare (IQWiG)

176. Rolapitant (prevention of nausea and vomiting in chemotherapy) - Benefit assessment according to §35a Social Code Book V

Rolapitant (prevention of nausea and vomiting in chemotherapy) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Rolapitant (Prävention von Übelkeit und Erbrechen bei Chemotherapie) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 30 August 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative (...) and legally binding. IQWiG Reports – Commission No. A17-26 Rolapitant (prevention of nausea and vomiting in chemotherapy) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A17-26 Version 1.0 Rolapitant (prevention of nausea and vomiting in chemotherapy) 30 August 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Rolapitant (prevention of nausea and vomiting

2017 Institute for Quality and Efficiency in Healthcare (IQWiG)

177. Etelcalcetide (secondary hyperparathyroidism) - Benefit assessment according to §35a Social Code Book V

Etelcalcetide (secondary hyperparathyroidism) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Etelcalcetid (sekundärer Hyperparathyreoidis- mus) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 30 August 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports (...) – Commission No. A17-25 Etelcalcetide (secondary hyperparathyroidism) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A17-25 Version 1.0 Etelcalcetide (secondary hyperparathyroidism) 30 August 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Etelcalcetide (secondary hyperparathyroidism) – Benefit assessment according to §35a Social Code Book V

2017 Institute for Quality and Efficiency in Healthcare (IQWiG)

178. Nivolumab (urothelial carcinoma) - Benefit assessment according to §35a Social Code Book V

Nivolumab (urothelial carcinoma) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Nivolumab (Urothelkarzinom) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 28 September 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A17-29 Nivolumab (...) (urothelial carcinoma) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A17-29 Version 1.0 Nivolumab (urothelial carcinoma) 28 September 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Nivolumab (urothelial carcinoma) – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission awarded on: 3 July 2017

2017 Institute for Quality and Efficiency in Healthcare (IQWiG)

179. Saxagliptin/metformin (type 2 diabetes) - Benefit assessment according to §35a Social Code Book V

Saxagliptin/metformin (type 2 diabetes) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Saxagliptin/Metformin (Diabetes mellitus Typ 2) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 25 October 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports (...) – Commission No. A17-33 Saxagliptin/metformin (type 2 diabetes mellitus) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A17-33 Version 1.0 Saxagliptin/metformin (type 2 diabetes mellitus) 25 October 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Saxagliptin/metformin (type 2 diabetes mellitus) – Benefit assessment according to §35a Social Code Book V

2017 Institute for Quality and Efficiency in Healthcare (IQWiG)

180. Ceritinib (non-small cell lung cancer) ? Benefit assessment according to §35a Social Code Book V

Ceritinib (non-small cell lung cancer) ? Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Ceritinib (nicht kleinzelliges Lungenkarzinom) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 25 October 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports (...) – Commission No. A17-32 Ceritinib (non-small cell lung cancer) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A17-32 Version 1.0 Ceritinib (non-small cell lung cancer) 25 October 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Ceritinib (non-small cell lung cancer) – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal

2017 Institute for Quality and Efficiency in Healthcare (IQWiG)

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>